SCHEMBL25366335

SCHEMBL25366335

Cc1n[nH]c2c(C)cc(N)cc12

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 3/20 0.46
ADORA2B P29275 3/20 0.46
ALDH1A1 P00352 2/20 0.33
TSHR P16473 2/20 0.33
JAK2 O60674 1/20 0.33
CYP1A2 P05177 1/20 0.33
POLB P06746 1/20 0.33
CYP3A4 P08684 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
RAB9A P51151 1/20 0.33
LMNA P02545 1/20 0.32
GSK3B P49841 1/20 0.31
FABP6 P51161 1/20 0.31
PDE10A Q9Y233 1/20 0.30
RPS6KA3 P51812 1/20 0.30
DYRK1A Q13627 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31147782 1.00 ADORA2A (0.46) ADORA2AADORA2BALDH1A1TSHRJAK2
SCHEMBL25367250 0.82 ADORA2A (0.46) ADORA2AADORA2BALDH1A1TSHR
SCHEMBL20110645 0.80 ADORA2A (0.33) ADORA2AADORA2BALDH1A1TSHRJAK2
SCHEMBL22889757 0.80 CHEK1 (0.35) ALDH1A1TSHRJAK2CYP1A2POLB
SCHEMBL1144415 0.75 ADORA2A (0.46) ADORA2AADORA2BTSHRJAK2MAPT
SCHEMBL13122195 0.75 ADORA2A (0.46) ADORA2AADORA2BTSHRCYP1A2CYP3A4
SCHEMBL13122251 0.75 ADORA2A (0.50) ADORA2AADORA2BTSHRDYRK1A
SCHEMBL25366793 0.74
SCHEMBL13672534 0.73 ADORA2A (0.44) ADORA2AADORA2BALDH1A1TSHRJAK2
SCHEMBL13675149 0.72 ADORA2A (0.43) ADORA2AADORA2BALDH1A1TSHRGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4476208-A1 GLP-1R MODULATING COMPOUNDS Ascletis Bioscience Co., Ltd. (CN) 2024-12-18 EP disclosed
WO-2023164358-A1 GLP-1R MODULATING COMPOUNDS ASCLETIS BIOSCIENCE CO., LTD. (CN) 2023-08-31 WO disclosed
WO-2023164358-A1 GLP-1R MODULATING COMPOUNDS ASCLETIS BIOSCIENCE CO., LTD. (CN) 2023-08-31 WO disclosed
US-20230271949-A1 GLP-1R MODULATING COMPOUNDS ASCLETIS BIOSCIENCE CO., LTD. (CN) 2023-08-31 US disclosed
US-20230271949-A1 GLP-1R MODULATING COMPOUNDS ASCLETIS BIOSCIENCE CO., LTD. (CN) 2023-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271949-A1 GLP-1R MODULATING COMPOUNDS GLP1R, GIPR, GPR119 ADORA2A 995/4885ADORA2B 1179/4885ALDH1A1 3386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.